Is it Possible to Predict The Market Access of a New Pharmaceutical in Germany? A Systematic Evaluation of Federal Joint Committee Decisions on Early Benefit Assessments According to The German Law For Reforming The Market of Pharmaceuticals. | Value Health;17(7): A437, 2014 Nov. | MEDLINE

Conteúdo principal 1 Busca 2 Rodapé 3

+A A -A Alto contraste

Biblioteca Virtual em Saúde

Secretaria Municipal da Saúde de São Paulo

português

Localizar descritor de assunto Busca Avançada

Is it Possible to Predict The Market Access of a New Pharmaceutical in Germany? A Systematic Evaluation of Federal Joint Committee Decisions on Early Benefit Assessments According to The German Law For Reforming The Market of Pharmaceuticals.

Schwander, B; Banz, K; Kaier, K; Walzer, S.

Afiliação

Schwander B; AHEAD GmbH, Loerrach, Germany.
Banz K; Outcomes International, Basel, Switzerland.
Kaier K; University of Freiburg, Freiburg, Germany.
Walzer S; MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany.

Value Health ; 17(7): A437, 2014 Nov.

Article em En | MEDLINE | ID: mdl-27201163

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2014 Tipo de documento: Article